The etiology of the disease is still unknown 3 . Recent evidences suggest that the underlying disorder may be insulin resistance (IR) and hyperinsulinemia causing excess androgen production 4 . Insulin resistance is a common lesion in both obese and non-obese PCOS women, but obesity contributes an additional component to IR in obese PCOS 5 . Although the reported incidence of insulin resistance varies, it is estimated to be 50% in PCOS 6 . There are several mechanisms for the state of insulin resistance: peripheral target tissue resistance, decreased hepatic clearance or increased pancreatic sensitivity 7 . In PCOS, peripheral insulin resistance is due to a defect beyond activation of the receptor kinase 8 . This would suggest no abnormality in the number of receptors or in receptor function; the impaired insulin signal for glucose transport may be due to a post-receptor problem.
There is an impressive correlation between the degree of hyperinsulinemia, and hyperandrogenism 9 . Most of the evidences support hyperinsulinemia as the primary factor, since turning off the ovary with a GnRH
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agonist does not change the hyperinsulinemia or insulin resistance 10 . Marked hyperinsulinemia synergizes with LH to stimulate ovarian androgen production causing ovarian theca cell hyperplasia, anovulation, menstrual disturbance and hirsutism.
In a state of insulin resistance, the pancreas produces an increase amount of insulin in response to normal metabolic homeostasis. Diabetes develops when this increased production cannot keep up with the metabolic needs and relative insulin deficiency occurs. Increased body size and increased amount of visceral fat are associated with worsening insulin sensitivity 11 . However, insulin resistance is also seen in lean patients with PCOS 6,12 .
Materials and Methods:
The study was conducted at CARE, department of Obstetrics and Gynecology and Biomedical Research Group, BIRDEM hospital during the period of January 2006-Decemember 2008.
A total number of 103 PCOS women of reproductive age (15-40 years) were included in the study. An informed consent was obtained from the subjects before the study.
According to Rotterdam criteria 2003, PCOS was diagnosed by oligomenorrhea (menstrual cycle interval >35 days but <6 months duration) or amenorrhea (if no menstruation for 6 months or more), and one or more of the following criteria such as subfertility, obesity, hirsutism, cystic acne, ultrasound evidence of bilateral enlarged ovaries with multiple (10 or more) small subcortical follicles (2-10 mm in diameter).
PCOS with known diabetes were excluded from the study. Patients with other endocrine disease (for e.g. hyperadrenalism, hypothyroidism) were excluded from the study.
Oral glucose tolerance test (OGTT) was performed in all subjects following the WHO criteria (1999). Blood samples were taken after overnight (8-12 hrs) fasting condition and then 2 hrs after 75 gram of glucose intake. Glucose and insulin levels were measured from both fasting sample and 2 hrs after glucose load. Patients were grouped in three groups-NGT (nonglucose tolerance), IGT (impaired glucose tolerance) and Type 2 DM according to WHO criteria.
Serum insulin (fasting and 2 hrs after glucose load) was assayed by chemiluminescence-based ELISA technique 13 using automated analyzer (IMMULITE, USA) with a commercial kit (Diagnostic Products Corporations, USA) (Appendix II).
Calculation of β β β β β-Cell Function and Insulin Sensitivity
Insulin secretory capacity (as assessed by insulin secretion HOMA â %) and insulin resistance (as assessed by insulin sensitivity HOMA S %) were calculated from fasting blood glucose (mmol/L) and fasting plasma insulin (pmol/l) values by homeostasis model assessment (HOMA) using HOMA-CIGMA software 14 .
The data were expressed as the mean ±SD (standard deviation) median, range, number and % as appropriate. Students unpaired t test, Mann-Whitney U test and X 2 was used for data analysis. Pearson correlation was performed to determine the association between different variables of interest. p-value of <0.05 was considered statistically significant. All statistical analyses were performed with the SPSS (Statistical Package for Social Science) software for Windows version 11.5 (SPSS, Inc. Chicago, IL, USA).
Results:
Clinical Characteristics of the study subjects PCOS were in reproductive age (15-36 years), mean age 24.4±5.18 years. Mean height of the subjects were 1.57±0.087 meter, weight was 62.08 ± 20.15 kg, and BMI was 25.84±5.54kg/ m 2 . The detailed anthropometry was shown in Table 1 . Of these 103 PCOS women, typical physical characteristics, such as acne, hirsutism was present in 91.3% cases and 48.5% PCOS had family history of diabetes. Insulin sensitivity and â cell function of different groups of PCOS Insulin sensitivity (Homa %S) was significantly decreased in IGT and T2 DM when compared with NGT (p=0.015, 0.042 respectively) but there was no significant difference in â cell function (Homa %B) in the three groups of PCOS (Table 5) . 
Discussion:
In the present study we observed that both fasting and glucose-stimulated insulin were significantly higher in IGT with PCOS than NGT with PCOS. But no difference of fasting and glucose-stimulated insulin was observed between type 2 DM and NGT PCOS.
Ehrmann et al 15 also found glucose stimulated insulin level of type 2 DM PCOS was lower than normal PCOS. Insulin-glucose ratio (after glucose load) was significantly lower in type 2 DM with PCOS when compared with NGT with PCOS. These results indicate that there may be an inappropriately low insulin response to glucose in Type 2 DM as there could be some â cell secretory defects.
We found that both IGT and type 2 DM were more insulin resistant than NGT with PCOS, but no difference was found between IGT vs. type 2 DM. So insulin resistance was a prime factor for developing IGT in PCOS and â cell secretory dysfunction was also an important risk factor for the developing type 2 DM. Lillioja et al 16 has found consistently a significant decrease in insulin meditated glucose disposal in both lean and PCOS women.
It is now clear that PCOS is often associated with profound insulin resistance as well as with defects in insulin secretion. These abnormalities, together with obesity, explain the substantially increased prevalence of glucose intolerance in PCOS. Moreover, since PCOS is an extremely common disorder, PCOSrelated insulin resistance is an important cause of NIDDM in women.
PCOS women also have impaired fibrinolytic activity with increased circulating levels of plasminogen activator inhibitor, PAI-1. Elevated PAI-1 levels are associated with insulin resistance and are considered an independent cardiovascular risk factor by increasing the risk of intravascular thrombosis. Several cross-sectional studies suggest that PCOS women may indeed be at increased risk for cardiovascular disease.
Conclusion:
Insulin resistance is a major pathophysiologic feature of IGT in PCOS; however, β cell secretory defect is associated with type 2 DM in these subjects.
Women with PCOS are at high risk for gestational diabetes and in long term development of type 2 DM.
Therefore, an early diagnosis of insulin resistance is crucial to reduce the incidence and severity of these potent risks.
